Table 2

 Selected characteristics of studies investigating Anda-TB (Anda Biologicals, Strasbourg, France) for the diagnosis of extrapulmonary tuberculosis

ReferenceData collectionVerificationReference standardDisease siteCountryComparison groupIg classNo. of participants*Sensitivity (95% CI)Specificity (95% CI)
TB, tuberculosis; Ig, immunoglobulin; NR, not reported.
The treatment status of cases was not reported for reference 45. For all other studies, patients were either not on treatment or on treatment for <14 days at the time serum was obtained.
*Number of participants with tuberculosis/without tuberculosis.
Alifano(1998, a)41RetrospectiveDifferentialCulture and/or histologyMultipleItalyMixed diseaseIgG42/440.74 (0.58 to 0.86)0.93 (0.81 to 0.99)
Alifano(1998, b)41RetrospectiveDifferentialCulture and/or histologyMultipleItalyMixed diseaseIgA42/440.69 (0.53 to 0.82)0.89 (0.75 to 0.96)
Banerjee(2003, a)42RetrospectiveNRHistologyLymph nodeIndiaHealthyIgG30/320.43 (0.25 to 0.63)0.59 (0.41 to 0.76)
Caminero(1993)43ProspectiveCompleteCulture and/or histologyPleuraSpainPleural TB suspectsIgG30/480.53 (0.34 to 0.72)1.00 (0.93 to 1.00)
Caminero(1994)44ProspectiveDifferentialCulture and/or histologyMultipleCanary IslandsNon-TB respiratoryIgG56/310.32 (0.20 to 0.46)0.94 (0.79 to 0.99)
Gevaudan(1992, a)45RetrospectiveDifferentialCulture and/or histologyLymph nodeFranceMixed diseaseIgG26/1941.00 (0.87 to 1.00)0.76 (0.69 to 0.82)
Gevaudan(1992, b)45RetrospectiveDifferentialCulture and/or histologyLymph nodeFranceMixed diseaseIgM26/1940.23 (0.09 to 0.44)0.95 (0.91 to 0.98)
Gevaudan(1992, c)45RetrospectiveDifferentialCultureDisseminated/miliary (primary)FranceMixed diseaseIgG56/1940.95 (0.85 to 0.99)0.76 (0.69 to 0.82)
Gevaudan(1992, d)45RetrospectiveDifferentialCultureDisseminated/miliary (primary)FranceMixed diseaseIgM56/1940.32 (0.20 to 0.46)0.95 (0.91 to 0.98)
Gevaudan(1992, e)45RetrospectiveDifferentialCultureDisseminated/miliary (post-primary)FranceMixed diseaseIgG25/1941.00 (0.86 to 1.00)0.76 (0.69 to 0.82)
Gevaudan(1992, f)45RetrospectiveDifferentialCultureDisseminated/miliary (post-primary)FranceMixed diseaseIgM25/1940.00 (0.00 to 0.14)0.95 (0.91 to 0.98)
Gevaudan(1992, g)45RetrospectiveDifferentialCultureGenitourinaryFranceMixed diseaseIgG34/1941.00 (0.90 to 1.00)0.76 (0.69 to 0.82)
Gevaudan(1992, h)45RetrospectiveDifferentialCultureGenitourinaryFranceMixed diseaseIgM34/1940.00 (0.00 to 0.10)0.95 (0.91 to 0.98)
Kunter(2003, a)46ProspectiveDifferentialCulturePleuraTurkeyNon-TB respiratoryIgG88/370.26 (0.17 to 0.37)0.86 (0.71 to 0.96)
Kunter(2003, b)46ProspectiveDifferentialCulturePleuraTurkeyNon-TB respiratoryIgM88/370.48 (0.37 to 0.59)0.92 (0.78 to 0.98)
Kunter(2003, c)46ProspectiveDifferentialCulturePleuraTurkeyNon-TB respiratoryIgG and IgM88/370.59 (0.48 to 0.70)0.81 (0.65 to 0.92)
Luh(1996)47ProspectiveNRCultureMultipleTaiwanMixed diseaseIgG35/2240.63 (0.45 to 0.79)0.92 (0.88 to 0.96)